Skip to content

Reparel Knee Sleeve vs. TED Hose for Post-op Swelling, Pain and Range of Motion After Total Knee Replacement

Post-operative Comparison Between Standard Gradient Compression Dressing vs. Non-Compressive Bioactive Garment on Pain, Swelling and Range of Motion Following Total Knee Arthroplasty

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04751942
Enrollment
23
Registered
2021-02-12
Start date
2023-10-20
Completion date
2025-01-21
Last updated
2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis Knees Both

Keywords

post-operative swelling, total knee arthroplasty, TKA, TED hose, photobiomodulation

Brief summary

This prospective study will evaluate pain, swelling, ROM as well as narcotic use in post-operative total knee arthroplasty patients using novel Non-Compressive Bioactive Garment (NCBG) versus current standard of care gradient compression stocking (Thrombo-Embolic-Deterrent or TED hose). If NCBG proves to be more effective in these outcome areas, it will provide a new and comfortable way to reduce patient pain and swelling immediately following surgery

Detailed description

Total knee arthroplasty (TKA) is one of the most popular surgical procedures today. It is designed and proven to effectively reduce pain caused by end-stage osteoarthritis. Despite its achievements, up to 25% of patients remain dissatisfied after the procedure due to lingering pain, amongst other complaints. Post-operative swelling of the knee and leg is thought to be a contributor to this persistent pain. Traditionally, a standard gradient compression stocking is applied to the knee and leg after surgery to reduce this pain and swelling. However, due to ineffectiveness or patient non-compliance, compression stockings are often not entirely successful at preventing edema. The recently developed NCPS is a lower extremity garment comprised of a technical fabric that is thought to be able to prevent edema and reduce pain all in a comfortable, user-friendly manner. The purpose of this study is to determine if the NCPS is effective at improving post-operative pain, swelling, ROM and analgesic use associated with TKA. Pain and prolonged recovery time associated with post-operative swelling are two factors that contribute to patient dissatisfaction following TKA. Swelling of the knee following TKA is caused by intraarticular bleeding and inflammation of the periarticular tissues, which can lead to a decrease in functional performance including pain and delayed rehabilitation. In a study by Noble et al, 1/3 of dissatisfied patients reported that their knees swelled at least once per week, leading to pain and discomfort1. Decreased quadriceps strength following knee surgery has been shown to prolong recovery1-8. Fahrer et al showed that knee effusions inhibited reflex neurons and altered kinetics and muscle activity in quadriceps, which ultimately causes decreased strength2. Holm et al later showed us that knee swelling played a part in post-operative quadriceps strength following TKA3. Ultimately, if post-operative swelling can effectively be reduced, patient recovery could be expedited and patient satisfaction could be improved. Compression stockings have been utilized to attempt to reduce post-operative swelling. Compression works to prevent swelling by reducing the hydrostatic pressure in the leg. Reducing hydrostatic pressure prevents the capillaries from oozing and allows blood to move freely from the superficial to the deep venous system, subsequently allowing excess fluid to flow away from the interstitial space9. More recently, the use of gradient compression stocking following TKA has come into question for its efficacy. While the application of external pressure from these gradient compression stocking is beneficial for a period, they are often unable to exert a sufficient amount of pressure long enough to prevent painful edema for an extended amount of time. A study by Bowling et al showed that these garments showed sufficient compression during the first few hours after surgery, but the pressure they applied dropped with time and required daily measurements and refitting to maintain appropriate and therapeutic compression10. This poses a problem not only medically, but financially as well. These compression stockings lose their fit so quickly, new ones must be prescribed frequently, leading to costly bills for the patient. It's clear that compression stockings are not as effective as once thought when it comes to controlling pain and swelling post-operatively. A potential solution to the problems posed by traditional compression stocking is the NCPG. The garment is comprised of a semi-conductive material ground to nanoparticles that are embedded into the fibers, formed into a three-dimensional woven fabric for optimized comfort. Instead of relying on compression, NCPS utilizes the body's own thermal energy to generate infrared energy. The infrared energy generated is reflected back at the body and modifies cellular activity at the level of the mitochondria through a process known as photobiomodulation14-15. This process of photobiomodulation is hypothesized to improve swelling and tissue healing by increasing the activity of mitochondria and the availability of cellular energy in the form of ATP. This study seeks to determine if NCPS use of infrared energy is more successful at reducing pain and swelling following TKA than traditional gradient compression dressing. We will enroll 100 subjects throughout all sites involved in the study. Patients will be recruited in the office setting after all non-operative modalities for controlling pain associated with end-stage osteoarthritis of the knee have been exhausted. Patients will then be presented with the option of total knee replacement. After patient has agreed to undergo TKA, patients will then be asked (in a face-to-face setting) if they would like to participate in the study. Patients will be approached in the office setting after it has been determined that they have failed conservative management of advanced knee arthritis. Patients will be in the surgeons' clinic behind closed doors with the performing surgeon and potentially other members of the research team. Consent will be obtained in the office after scheduling total knee arthroplasty procedure. The consent process is expected to take 30 minutes, but more time is available to ensure that patients have all their questions answered prior to signing the consent form. Patients will be enrolled in study prior to surgery, outlined above in the consent process. On the day of surgery, patients will arrive and will be situated in the pre-operative holding area. A trained member of the research team will meet the patient in the pre-operative holding area and will measure the circumference of the patient's leg at the mid-thigh, mid-knee and mid-calf. The patient's range of motion of the operative leg will be measured in flexion and extension. All measurements will be recorded in redcap. The patient will then go on to have their primary total knee arthroplasty by standard of care procedure. Both cruciate retaining and posterior stabilized total knee replacement designs will be included in the study. Following closure of the surgical site and placement of a post-operative occlusive dressing, the operative leg will be measured once more for circumference and range of motion, and the values will be entered into redcap. The patient will then be placed in their randomized post-operative sleeve/device and will be transferred to the PACU and will receive the standard post-operative treatment. On post-operative day one, patient's will be seen and evaluated in their inpatient rooms. Their leg measurements will be taken again with the knee sleeve/compressive gradient dressing pulled down. Patient's skin will be inspected for any reactions to the sleeve and a standard post-operative examination will be performed to ensure no neurovascular compromise, blood clots, infections or other post-operative complications. Patients will likely be discharged on post-operative day 1. Patients that have not been discharged on post-operative day 1 will not be measured on post-operative day 2. Patients will be provided with a journal that they will use every daily to track their pain based on a visual analog scale and their narcotic consumption (number of Percocet or tramadol pills). Patients will also use their journal to log the number of hours they wore their sleeve each day. Patients will continue to log the number of pain medications taken and hours wearing the sleeve for 6 weeks Sleeves will be worn morning and night removing them only for hygiene and washing of sleeve for 2 weeks. After 2 weeks, the patient's will wear the sleeve as much as they can tolerate day and night. At 6 weeks, sleeves will be discontinued all together. Final ROM and Circumference Measurements will be obtained at 12 weeks post-operative mark. Patients will be asked to fill out the Knee Society Score questionnaire at the time of consent and at each post-operative visit. The Reparel leg sleeve is the experimental device being investigated in this study. It is intended to improve swelling in the post-operative knee. Allscripts Electronic Medical Records will be used to collect data about patients during their inpatient, post-operative stay. UH Care ambulatory EMR and Medent EMR will be used in the outpatient setting to collect data and track post-operative clinic visits. The enrollment period will be 1 year from the time of the first patient enrolled in the study. The enrollment period may be expanded to allow for the investigators to reach their goal of 100 patients. The total amount of time each patient will be involved in the study will be 12 weeks. Patients will only be required to wear the post-operative sleeve/dressing for 6 weeks post-operatively. Patients will continue to record their narcotic consumption and pain scores for 12 weeks post-operatively Date to be collected: Mid-thigh, mid-knee, and mid-calf measurements ROM measurements in knee flexion and knee extension Visual analog Pain scale Knee society score (KSS) Narcotic consumption Name Medical record number Surgeon weight Data Analysis Plan: Demographics will be reported using descriptives such as count data and percentages. Differences between groups at baseline (pre-op) will be reported using two-tailed independent t-tests for continuous variables, and chi-square or Fisher's Exact tests for categorical data, as appropriate. The primary outcomes of range of motion, leg circumference, and pain ratings will be compared post-op between conditions using two-tailed independent t-tests. Should clinically relevant demographics differ significantly between conditions pre-op (baseline), post-op comparisons will instead be conducted using one-way ANCOVAs controlling for differences at pre-op (baseline). These comparisons will additionally be made at multiple additional time-points throughout a 12-week post-op time period. A priori power analyses were calculated for two-tailed independent t-tests for each primary outcome, using an alpha of .05, power = .80. Each of these are reported and the average of these numbers is used to calculate the final sample size. Clinically significant reductions in pain are defined as a 2-point change with a standard deviation of 2.5 using a 10-point scale; 84 patients were estimated. Clinically significant changes in range of motion are defined as: 10 degrees of difference from a 0-140 degree estimated range of values. Clinically significant changes in leg circumference are defined as: 1 cm difference in leg circumference using a 15-30 estimated range of values. To identify medium effect sizes of .55, 106 patients were estimated. Averaging these values, 99 patients were estimated. To ensure equal numbers of patients in each condition, 100 patients will be recruited for this study. The data will be monitored every 10 patients to assess for completeness, accuracy and adherence to the protocol. We will also be monitoring for any obvious safety concerns that may arise. There will not be a designated safety team assigned.

Interventions

DEVICENon-compressive Bioactive Garment

patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty

DEVICEthrombo-embolic deterrent

patients will be randomized to wear the gold standard TED hose following total knee arthroplasty

Sponsors

University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

prospective randomized control cohort study

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* Primary unilateral Total Knee Replacement - Cruciate retaining and Posterior stabilized designs

Exclusion criteria

* Leg circumference \> 23 in. * Allergy to silicone/polyester * Current DVT * Primary Inflammatory Type arthritis (i.e. rheumatoid arthritis) * Inability to follow standardized post op and rehab protocols * Lymphedema * History of Vascular Bypass Surgery on Operative Limb (i.e. Fem-Pop or Fem-Fem) * Chronic Narcotic Use History

Design outcomes

Primary

MeasureTime frameDescription
Change in Leg Circumference (cm)Preop, 2 weeks post op, 6 weeks post-op, 3 months post-opcircumference of the leg will be measured pre-operatively, immediately post operatively, and at regular intervals post-operatively.
Change in Pain Score (1-10)Pre-op, 1 week Post-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-oppatient's subjective pain scores will be recorded daily in a pain journal using a visual analog scale from 1-10, values are grouped into mild (1-3), moderate (4-6), and severe (7-10) pain.
Change in Range of MotionPre-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-oppatients passive flexion range of motion will be tested pre-operatively, immediately post-operatively, and at regular intervals post-operatively
Change in Narcotic Consumption1 week Post-op, 2 weeks Post-op. 6 weeks Post-op, 3 months Post-opthe narcotic consumption in Milligrams of morphine equivalents (MME) per day will be recorded post-operatively while in the hospital and will be self reported by the patient in a journal as number of pills taken
Change in Knee Society Score (KSS)Pre-op, 1 week Post-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-opa validated system that combines an objective physician-derived component with a subjective patient-derived component that evaluates pain relief, functional abilities, satisfaction, and fulfillment of expectations. Patients will fill out this questionnaire pre-operatively and at each post-operative visit. With lower scores indicating lower pain/difficulty with daily activities and higher scores indicating higher pain/difficulty with daily activities.

Countries

United States

Participant flow

Participants by arm

ArmCount
Non-compressive Bioactive Garment
The non-compressive bioactive garment is a commercially available garment that is designed to reflect infrared waves generated by the wearer back into the soft tissue surrounded by the garment. The reflection of the infrared waves is intended to improve pain and swelling at the site. Patients following Total knee replacement are intended to wear morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks. Non-compressive Bioactive Garment: patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
0
Thrombo-Embolic Deterrent
a gradient compression stocking that is currently the gold standard for deterring thromboembolic events and assisting with post-operative swelling after total knee replacements. Patients following Total knee replacement are intended to wear the TED hose morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks. thrombo-embolic deterrent: patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
0
Total0

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up96

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 140 / 9
other
Total, other adverse events
0 / 140 / 9
serious
Total, serious adverse events
0 / 142 / 9

Outcome results

Primary

Change in Knee Society Score (KSS)

a validated system that combines an objective physician-derived component with a subjective patient-derived component that evaluates pain relief, functional abilities, satisfaction, and fulfillment of expectations. Patients will fill out this questionnaire pre-operatively and at each post-operative visit. With lower scores indicating lower pain/difficulty with daily activities and higher scores indicating higher pain/difficulty with daily activities.

Time frame: Pre-op, 1 week Post-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-op

Population: Data was collected for participants that showed at each follow up apt, some did not come to all follow up apts.

ArmMeasureGroupValue (MEAN)Dispersion
Non-compressive Bioactive GarmentChange in Knee Society Score (KSS)1 week Post-op33.33 units on a scaleStandard Deviation 14.45
Non-compressive Bioactive GarmentChange in Knee Society Score (KSS)6 weeks Post-op10.63 units on a scaleStandard Deviation 8.01
Non-compressive Bioactive GarmentChange in Knee Society Score (KSS)2 weeks Post-op23.92 units on a scaleStandard Deviation 14.3
Non-compressive Bioactive GarmentChange in Knee Society Score (KSS)3 months Post-op11.2 units on a scaleStandard Deviation 7.96
Non-compressive Bioactive GarmentChange in Knee Society Score (KSS)Pre-op38.29 units on a scaleStandard Deviation 16.25
Thrombo-Embolic DeterrentChange in Knee Society Score (KSS)3 months Post-op22.67 units on a scaleStandard Deviation 23.57
Thrombo-Embolic DeterrentChange in Knee Society Score (KSS)Pre-op40.33 units on a scaleStandard Deviation 13.81
Thrombo-Embolic DeterrentChange in Knee Society Score (KSS)1 week Post-op33 units on a scaleStandard Deviation 16.9
Thrombo-Embolic DeterrentChange in Knee Society Score (KSS)2 weeks Post-op31.25 units on a scaleStandard Deviation 23.68
Thrombo-Embolic DeterrentChange in Knee Society Score (KSS)6 weeks Post-op15.67 units on a scaleStandard Deviation 4.78
Primary

Change in Leg Circumference (cm)

circumference of the leg will be measured pre-operatively, immediately post operatively, and at regular intervals post-operatively.

Time frame: Preop, 2 weeks post op, 6 weeks post-op, 3 months post-op

Population: Data was collected for participants that showed at each follow up apt, some did not come to all follow up apts.

ArmMeasureGroupValue (MEAN)Dispersion
Non-compressive Bioactive GarmentChange in Leg Circumference (cm)Pre-op44.06 Leg circumference (cm)Standard Deviation 3.77
Non-compressive Bioactive GarmentChange in Leg Circumference (cm)2 weeks Post-op44.18 Leg circumference (cm)Standard Deviation 4.25
Non-compressive Bioactive GarmentChange in Leg Circumference (cm)6 weeks Post-op45.17 Leg circumference (cm)Standard Deviation 5.85
Non-compressive Bioactive GarmentChange in Leg Circumference (cm)3 months Post-op46.36 Leg circumference (cm)Standard Deviation 5.65
Thrombo-Embolic DeterrentChange in Leg Circumference (cm)3 months Post-op45.89 Leg circumference (cm)Standard Deviation 1.87
Thrombo-Embolic DeterrentChange in Leg Circumference (cm)Pre-op44.77 Leg circumference (cm)Standard Deviation 6.34
Thrombo-Embolic DeterrentChange in Leg Circumference (cm)6 weeks Post-op46.14 Leg circumference (cm)Standard Deviation 2.16
Thrombo-Embolic DeterrentChange in Leg Circumference (cm)2 weeks Post-op49.99 Leg circumference (cm)Standard Deviation 5.19
Primary

Change in Narcotic Consumption

the narcotic consumption in Milligrams of morphine equivalents (MME) per day will be recorded post-operatively while in the hospital and will be self reported by the patient in a journal as number of pills taken

Time frame: 1 week Post-op, 2 weeks Post-op. 6 weeks Post-op, 3 months Post-op

Population: Data was collected for participants that showed at each follow up apt, some did not come to all follow up apts.

ArmMeasureGroupValue (MEAN)Dispersion
Non-compressive Bioactive GarmentChange in Narcotic Consumption1 week Post-op1.56 Milligrams of morphine equivalents.dayStandard Deviation 1.42
Non-compressive Bioactive GarmentChange in Narcotic Consumption2 week Post-op1.58 Milligrams of morphine equivalents.dayStandard Deviation 1.26
Non-compressive Bioactive GarmentChange in Narcotic Consumption6 weeks Post-op0.25 Milligrams of morphine equivalents.dayStandard Deviation 0.43
Non-compressive Bioactive GarmentChange in Narcotic Consumption3 months Post-op0 Milligrams of morphine equivalents.dayStandard Deviation 0
Thrombo-Embolic DeterrentChange in Narcotic Consumption3 months Post-op0 Milligrams of morphine equivalents.dayStandard Deviation 0
Thrombo-Embolic DeterrentChange in Narcotic Consumption1 week Post-op2 Milligrams of morphine equivalents.dayStandard Deviation 1.79
Thrombo-Embolic DeterrentChange in Narcotic Consumption6 weeks Post-op0 Milligrams of morphine equivalents.dayStandard Deviation 0
Thrombo-Embolic DeterrentChange in Narcotic Consumption2 week Post-op2.5 Milligrams of morphine equivalents.dayStandard Deviation 2.35
Primary

Change in Pain Score (1-10)

patient's subjective pain scores will be recorded daily in a pain journal using a visual analog scale from 1-10, values are grouped into mild (1-3), moderate (4-6), and severe (7-10) pain.

Time frame: Pre-op, 1 week Post-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-op

Population: Data was collected for participants that showed at each follow up apt, some did not come to all follow up apts.

ArmMeasureGroupValue (MEAN)Dispersion
Non-compressive Bioactive GarmentChange in Pain Score (1-10)1 week Post-op3.67 score on a scaleStandard Deviation 1.25
Non-compressive Bioactive GarmentChange in Pain Score (1-10)6 weeks Post-op1.25 score on a scaleStandard Deviation 0.97
Non-compressive Bioactive GarmentChange in Pain Score (1-10)2 weeks Post-op2.92 score on a scaleStandard Deviation 1.5
Non-compressive Bioactive GarmentChange in Pain Score (1-10)3 months Post-op1.4 score on a scaleStandard Deviation 0.8
Non-compressive Bioactive GarmentChange in Pain Score (1-10)Pre-op4.07 score on a scaleStandard Deviation 1.8
Thrombo-Embolic DeterrentChange in Pain Score (1-10)3 months Post-op1.33 score on a scaleStandard Deviation 0.47
Thrombo-Embolic DeterrentChange in Pain Score (1-10)Pre-op4.44 score on a scaleStandard Deviation 1.64
Thrombo-Embolic DeterrentChange in Pain Score (1-10)1 week Post-op4 score on a scaleStandard Deviation 1.67
Thrombo-Embolic DeterrentChange in Pain Score (1-10)2 weeks Post-op4.25 score on a scaleStandard Deviation 2.44
Thrombo-Embolic DeterrentChange in Pain Score (1-10)6 weeks Post-op2 score on a scaleStandard Deviation 0.82
Primary

Change in Range of Motion

patients passive flexion range of motion will be tested pre-operatively, immediately post-operatively, and at regular intervals post-operatively

Time frame: Pre-op, 2 weeks Post-op, 6 weeks Post-op, 3 months Post-op

Population: Data was collected for participants that showed at each follow up apt, some did not come to all follow up apts.

ArmMeasureGroupValue (MEAN)Dispersion
Non-compressive Bioactive GarmentChange in Range of MotionPre-op121.85 DegreesStandard Deviation 13.81
Non-compressive Bioactive GarmentChange in Range of Motion6 weeks Post-op117.13 DegreesStandard Deviation 15.91
Non-compressive Bioactive GarmentChange in Range of Motion3 months Post-op113.4 DegreesStandard Deviation 5.12
Non-compressive Bioactive GarmentChange in Range of Motion2 weeks Post-op99.08 DegreesStandard Deviation 13.16
Thrombo-Embolic DeterrentChange in Range of Motion3 months Post-op115.33 DegreesStandard Deviation 7.76
Thrombo-Embolic DeterrentChange in Range of MotionPre-op116.88 DegreesStandard Deviation 25.61
Thrombo-Embolic DeterrentChange in Range of Motion2 weeks Post-op95.29 DegreesStandard Deviation 15.46
Thrombo-Embolic DeterrentChange in Range of Motion6 weeks Post-op114 DegreesStandard Deviation 13.59

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026